-+ 0.00%
-+ 0.00%
-+ 0.00%

AKESO ADVANCES IO2.0 + ADC2.0 STRATEGY: FIRST PATIENT DOSED IN PHASE II STUDY OF TROP2/NECTIN-4 BISPECIFIC ADC (AK146D1) COMBINED WITH IVONESCIMAB IN BREAST CANCER

Reuters·08/10/2026 04:06:27

Please log in to view news